Keyword Analysis & Research: esbl e coli bacteremia
Keyword Research: People who searched esbl e coli bacteremia also searched
Search Results related to esbl e coli bacteremia on Search Engine
-
IDSA 2023 Guidance on the Treatment of Antimicrobial Resistant …
https://www.idsociety.org/practice-guideline/amr-guidance/
WebThe trial included 66 patients with ESBL-producing E. coli pyelonephritis or cUTI (with confirmation of the presence of ESBL genes) randomized to either piperacillin-tazobactam 4.5 g IV every six hours or ertapenem 1 g IV every 24 hours. Clinical success was similar between both groups at 94% for piperacillin-tazobactam and 97% for ertapenem.
DA: 51 PA: 45 MOZ Rank: 25
-
Extended-spectrum beta-lactamases - UpToDate
https://www.uptodate.com/contents/extended-spectrum-beta-lactamases
WebMar 8, 2024 · Extended-spectrum beta-lactamases (ESBLs) are enzymes that confer resistance to most beta-lactam antibiotics, including penicillins, cephalosporins, and the monobactam aztreonam. Infections with ESBL-producing organisms have been associated with poor outcomes.
DA: 5 PA: 11 MOZ Rank: 38
-
Stanford De-escalation Guide for Gram-negative Bacteremia
https://med.stanford.edu/content/dam/sm/bugsanddrugs/documents/clinicalpathways/SHC-GNR-Bacteremia-de-escalation-guide.pdf
WebStanford De-escalation Guide for Gram-negative Bacteremia . Antibiotic Selection . Pathogens Preferred therapeutic options IF SUSCEPTIBLE . Switch to PO when clinically stable, able to take orals, no concern for absorption issues . E.coli, Klebsiella spp., Proteus spp, Citrobacter koseri. Ceftriaxone 2g IV q24h Ciprofloxacin 500mg PO BID
DA: 84 PA: 31 MOZ Rank: 38
-
Gram-negative Bloodstream Infection | Infectious Diseases …
https://idmp.ucsf.edu/content/gram-negative-bloodstream-infection
WebSep 29, 2021 · Criteria: Inclusion: Controlled source of infection. Received microbiologically active IV therapy for at least 48 hours. Clinically stable. No vasopressor requirements for at least 48 hours. Nomothermia (temperature between 36-38 degrees Celisus) x 48 hours without the administration of anti-pyretic medications.
DA: 44 PA: 78 MOZ Rank: 60
-
Bacteremia Caused by Extended-Spectrum Beta-Lactamase…
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204562/
WebMar 9, 2020 · The first ESBL-producing E. coli was identified in Mahosot Hospital, Vientiane, in 2004, and between 2004 and 2009, 9% of E. coli isolated from blood were ESBL producers. 11 A study of preschool children in and around Vientiane in 2011 found that 23% were colonized with ESBL-E, mainly E. coli …
DA: 60 PA: 42 MOZ Rank: 86
-
Ertapenem for the treatment of bloodstream infections due to ESBL
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867097/
WebFeb 22, 2016 · Data about the efficacy of ertapenem for the treatment of bloodstream infections (BSI) due to ESBL-producing Enterobacteriaceae (ESBL-E) are limited. We compared the clinical efficacy of ertapenem and other carbapenems in …
DA: 45 PA: 11 MOZ Rank: 74
-
Sepsis Caused by Extended-Spectrum Beta-Lactamase (ESBL) …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956035/
WebJul 21, 2016 · We found significant differences in clinical presentation of ESBL-E bacteremia due to K. pneumoniae compared to E. coli. As K. pneumoniae cases showed a more serious clinical presentation as E. coli cases and were associated with different risk factors, treatment and prevention strategies should be adjusted accordingly. Go to: …
DA: 21 PA: 74 MOZ Rank: 22
-
Duration of antibiotic treatment for Gram-negative bacteremia
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00479-5/fulltext
WebDec 1, 2022 · For patients hemodynamically stable and afebrile at 48 h prior to discontinuation, seven days of antibiotic therapy for enterobacterales bacteremia result in similar outcomes as 14 days, in terms of mortality, relapse, length of hospital stay, complications of infection, resistance emergence, and adverse events.
DA: 82 PA: 62 MOZ Rank: 94
-
Sepsis Caused by Extended-Spectrum Beta-Lactamase (ESBL
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0158039
WebJul 21, 2016 · Sepsis Caused by Extended-Spectrum Beta-Lactamase (ESBL)-Positive K. pneumoniae and E. coli: Comparison of Severity of Sepsis, Delay of Anti-Infective Therapy and ESBL Genotype | PLOS ONE. Share. Open Access. Peer-reviewed. Research Article.
DA: 38 PA: 22 MOZ Rank: 58
-
Initial empirical antibiotics of non-carbapenems for ESBL-producing E
https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-022-07881-7
WebNov 21, 2022 · Metrics. Abstract. Background. The efficacy of non-carbapenems as an empirical antibiotic for extended-spectrum β-lactamases (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia in children remains controversial.
DA: 6 PA: 7 MOZ Rank: 29